Recruiting for Treatment Study – video

This is a video that documents the experiences of three children who have participated in the pilot study of intranasal ketamine as a treatment for juvenile bipolar disorder. Dr. Demitri Papolos, Director of Research for JBRF, developed and implemented a pilot study to explore the efficacy of intranasal ketamine as a treatment for children who…

JBRF Genetic Study

The Goal The goal of the Genetics Study is to better understand the genetic basis of juvenile bipolar disorder.  Greater comprehension of the biological basis of the disorder will lead to better methods of prevention and treatment. Genetics 101 The human body is composed of trillions of cells.  Each one of these cells contains chromosomes.…

Ketamine clinical study kicks off!

A targeted treatment for children struggling with bipolar disorder. JBRF received approval from the U.S. Food and Drug Administration (“FDA”) to begin the clinical trial of a pharmaceutical agent to treat the symptoms of bipolar disorder in children. The clinical trial will study the efficacy and safety of the use of intranasal ketamine in the…

Press Release: FDA Approval

Maplewood, NJ – November 3, 2011The Juvenile Bipolar Research Foundation (“JBRF”) announced today that the Federal Drug Administration (“FDA”) has approved its submission of a request to study the use of intranasal ketamine in the treatment of children ages 6-12 with bipolar disorder who also have an identifiable biological marker associated with body temperature dysregulation.…